What is DURECT Corporation (DRRX) stock price today?

DURECT Corporation (DRRX) is currently trading at $1.91, down 1.04% today.

What is DRRX P/E ratio?

DURECT Corporation's P/E ratio is -9.41. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is DRRX return on equity (ROE)?

DURECT Corporation's return on equity (ROE) is -139.90%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is DURECT Corporation's market cap?

DURECT Corporation has a market capitalization of $59.31M.

NASDAQ · Drug Manufacturers - Specialty & Generic

DURECT Corporation (DRRX) Stock

$1.91 -1.04% NASDAQ: DRRX Healthcare

Valuation

Metric	Value
Price	$1.91
Market Cap	$59.31M
P/E Ratio	-9.41
P/B Ratio	15.06
P/S Ratio	77.23
EPS (TTM)	$-0.27
52-Week High	$2.64
52-Week Low	$0.48
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-139.90%
ROA	-52.05%
ROCE	-151.27%
Gross Margin	90.10%
Operating Margin	-903.91%
Net Margin	-845.96%
Debt/Equity	0.44
Current Ratio	0.98

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$30.0M	$14.0M	$19.0M	$9.0M	$2.0M
Operating Profit	$-13.0M	$-34.0M	$-35.0M	$-37.0M	$-19.0M
Net Profit	$-13.0M	$-36.0M	$-35.0M	$-28.0M	$-8.0M
EPS	$-0.67	$-1.61	$-1.55	$-1.20	$-0.27
Op Margin	-41.9%	-245.2%	-181.9%	-431.5%	-931.2%

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$76.0M	$92.0M	$60.0M	$45.0M	$18.0M
Total Liabilities	$36.0M	$34.0M	$35.0M	$30.0M	$9.0M
Cash	$21.0M	$50.0M	$43.0M	$28.0M	$11.0M
Borrowings	$26.0M	$24.0M	$23.0M	$21.0M	$2.0M

Latest News

Grieving Messi available for Miami in Leagues Cup clash AFP · Aug 12, 2026 Rio Tinto Aluminum Smelter Receives $1.8 Billion Government Bailout MT Newswires · Aug 12, 2026 Dow Jones Futures: Cisco, Coherent Are Earnings Movers Late After Nebius, Lumentum, CoreWeave Lead AI Rally Investor's Business Daily · Aug 12, 2026 FMS CAPITAL TRUST FULLY ALLOCATES OVER $110 MILLION IN FIRST YEAR WITH ACQUISITION OF FOUR HAMILTON SELF-STORAGE PROPERTIES CNW Group · Aug 12, 2026 MFS Founder Paresh Raja Launches Legal Claim to Block Bankruptcy Pursuit MT Newswires · Aug 12, 2026

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-39.0M	$-37.0M	$-26.0M	$-34.0M	$-19.0M
Investing Cash Flow	$9.0M	$15.0M	$20.0M	$-1.0M	$18.0M
Financing Cash Flow	$3.0M	$3.0M	$0	$24.0M	$0
Net Cash Flow	$-14.0M	$29.0M	$-6.0M	$-15.0M	$-17.0M
Free Cash Flow	$-39.0M	$-38.0M	$-26.0M	$-34.0M	$-19.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.05
EV / EBITDA	-8.64
FCF Yield	-8.96%
Quick Ratio	0.95
Interest Coverage	—
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHLAchilles Therapeutics plc	$1.48	+0.68%	-0.85	$60.83M	0.00%
HTBXHeat Biologics, Inc.	$2.38	+0.42%	-1.87	$61.07M	0.00%
LFWDLifeward Ltd.	$6.22	+1.97%	-0.35	$10.02M	0.00%
LIENChicago Atlantic BDC, Inc.	$9.04	-0.88%	6.83	$206.30M	14.32%
QLIQilian International Holding Group Limited	$5.41	-3.57%	-24.59	$38.68M	0.00%

About DURECT Corporation

DURECT Corporation is a biopharmaceutical enterprise dedicated to the research and development of innovative medicines, leveraging its epigenetic regulator and pharmaceutical platforms. The company provides the ALZET product range, which includes osmotic pumps and associated accessories vital for research studies conducted on mice, rats, and other laboratory animals. In its development pipeline, DURECT is advancing larsucosterol (DUR-928), an endogenous, orally administered small molecule. This compound, currently undergoing a Phase IIb clinical trial for alcohol-associated hepatitis, is designed to regulate lipid metabolism, stress and inflammatory pathways, and cellular survival and death. A Phase Ib clinical trial for patients with nonalcoholic steatohepatitis has also been successfully completed. Additionally, DURECT markets POSIMIR, a product aimed at managing post-surgical pain in adults by delivering bupivacaine for an extended period. The company also offers Methydur, a treatment for attention deficit hyperactivity disorder. Sales of the ALZET product line are managed by an in-house sales force across the United States and through an extensive network of distributors internationally, including Japan and Europe. DURECT Corporation engages in strategic collaborations and agreements with various partners, such as the Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd. Established in 1998, DURECT Corporation maintains its headquarters in Cupertino, California.

DURECT Corporation is headquartered in US.

DURECT Corporation (DRRX) stock trades at $1.91 with a market capitalization of $59.31M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.41, reflecting a net loss over the last twelve months, price-to-book of 15.06, price-to-sales of 77.23. Over the past 52 weeks the stock has ranged between $0.48 and $2.64, and currently trades 27.7% below its 52-week high.

On profitability, DURECT Corporation generates a return on equity (ROE) of -139.90% (negative, reflecting a net loss), return on capital employed of -151.27%, an operating margin of -903.91%, a net profit margin of -845.96%.

Official website: www.bauschhealth.com